Advertisement

Global Cervical Cancer Screening

  • Nenad Markovic
  • Olivera Markovic
Chapter

Abstract

The purpose of cervical cancer screening among healthy – asymptomatic – women is to detect the presence of lesions that could be developed into cervical cancer, and to remove them; thus, providing cure from cancer. Ultimately, cervical cancer screening test is saving lives of women in fertile periods.

Keywords

Cervical Cancer Cervical Cancer Screening Digital Technology Indian Woman Mobile Health 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    ACCP. Cervical cancer prevention. Fact Sheet. 10 key findings and recom-mendations for effective cervical cancer screening and treatment programs. Cited Internet http://www.alliance-cxca.org/. Cited September 25, 2007
  2. 2.
    Agoff SN, Lin P, Morihara J et al (2003) p16INK4a expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 16(7):665–673CrossRefPubMedGoogle Scholar
  3. 3.
    AHRQ, Agency for Healthcare Research and Quality. Patient Fact Sheet. 20 tips to help prevent medical errors. http://www.ahrq.gov/consumer/20tips.html on August 1 2007. Cited August 24, 2007
  4. 4.
    American Cancer Society Home. http://www.cancer.org. Cited September 17, 2007
  5. 5.
    American Cancer Society. Prevention & early detection. ACS guidelines for early detection of cancer. http://www.cancer.org/docroot/PED/content. Cited September 15, 2007
  6. 6.
    American Cancer Society Guidelines on nutrition and physical activity in cancer patients. http://caonline.amcancersociety.org. Cited August 17, 2007
  7. 7.
    Anonymous. Hysterectomy. Medical encyclopedia. http://www.answers.com/topic/hysterectomy. Cited June 30, 2007
  8. 8.
    Anonymous. Statistics about cervical cancer. WrongDiagnosis.com http://www.wrongdiagnosis.com/c/cervical_cancer/stats.html. Cited July 12, 2007
  9. 9.
    Anonymous. Chlamydial genital tract infections. Chlamydia as a cofactor in cervical cancer. http://www.chlamydiae.com/restricted/docs/infections/gentrac_cervical_cancer. Cited September 14, 2007
  10. 10.
    Anonymous. University of Florida Shands Cancer Center. Stress and depression frequent among women treated for gynecological cancers. http://www.ufscc.ufl.edu/patient/cancernews.aspx. Cited June 23, 2007
  11. 11.
    Anonymous. New biomarker for cervical cancer. Medical observer, December 1999. http://findarticles.com/articles/mi_m3230/is_12_31/ai. Cited July 4, 2007
  12. 12.
    Arrossi S, Sankaranayanan R, Parkin D. Incidence and mortality of cervical cancer in Latin America. IARC, WHO. http://www.scielosp.org/scielo.php?script=sci. Cited July 15, 2007
  13. 13.
    Arbyn M, Raifu AO, Autier P, et al (2007) Burden of cervical cancer in Europe: estimates for 2004. 2007 European Society for Medical Oncology. Ann Oncol online ISSN 1569–8041Google Scholar
  14. 14.
    ASCCP Practice recommendations. The cervix: histology. http://asccp.org/edu. Cited February 4, 2007
  15. 15.
    Austin R. Marshal. Information for ASC member posted on members list@cytopathology.org and ASCCP Home. http://www.asccp.org/consensus.shtml. Cited September 4, 2007
  16. 16.
    BBC News on April 9, 2007. Staining ‘spots cervical cancer’ http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/6518685.stm. Cited August 28, 2007
  17. 17.
    Beutner KR et al (1997) Human papilloma virus and human disease. Am J Med 102(5a):9–15. www.brown.edu/courses/Bio_160/Projects1999/path.html. Cited April 4, 2006
  18. 18.
    Bioscreening Industry News. November 7, 2005. TriPath Imaging, Inc. (NASDAQ) PRNewswire-First Call. New research study provides further evidence of strong correlation of TriPath Imaging ProEx C Biomarkers with biopsy evidence of high-grade cervical intraepithelial neoplasia (CIN 2+)Google Scholar
  19. 19.
    Bibbo M (1997) Comprehensive cytopathology. W.B. Saunders, PhiladelphiaGoogle Scholar
  20. 20.
    BioSciCon’s electronic Survey. Web Site link. http://www.surveymk.com/s.aspx?sm=aKALIgzj7AwSthXcp0nI1w_3d_3d. Cited September 25, 2007
  21. 21.
    BioSciCon’s web portal: http://www.bioscicon.com
  22. 22.
    BioSciCon’ MarkPap Self test. http://bioscicon.com/productsindev.html
  23. 23.
    Biswas R. Rural Indian women face heightened cervical cancer risks. PRB Population Reference Bureau. http://www.prb.org/Articles/2004/RuralIndian. Cited June 8, 2007
  24. 195.
    Markovic N. BioSciCon presents the MarkPap technology. Larta-CAP Venture Forum 2007, San Francisco, May 2007. http://www.theventureforum.com/PresentingCompaniesList.asp
  25. 196.
    Markovic N, Markovic O. Biomarker plus. 55th annual meeting of the American Society of Cytopathology, Nov 2007, Houston. Cancer cytopathology Suppl. 11/5,385,2007. Click here to download the abstract. (PDF format)
  26. 197.
    Markovic N, Markovic O. Ask for women’ s opinion first. Teaching and computer session. FASEB experimental biology, 2008. Today’s research: tomorrow’s health. San Diego California, April 5–9, 2008. Click here to download the abstract
  27. 198.
    Prabal D, Wenkateswaran Y, Bhatla N, Markovic O, Verma K (2008) Cervical acid Phosphatase detection: a guide to abnormal cells in cytology smear screening for cervical cancer. J Cytol 25(1):1–5. Click here to view the article
  28. 199.
    Iyer VK, Mathur SR, Bhatla N, Markovic O. Evaluation of cytology screening strategies for cervical cancer in resource poor settings. 18th International Congress of Cytology, Paris, May 2013. Click here to view the abstract
  29. 200.
    Neha B, Agrawal PM, Santwani M (2015) Staudy of CAPPAP versus conventional papa in suspicious cervical lesions. Int J Res Med 4(1):102–108Google Scholar
  30. 201.
    Niranjan J, Prakash CJ (2015) Cervical acid Phosphatase: evaluation as a an adjuvant to Papanicolaou smears screening in cervical cancer detection. J Evid Based Med Healthc 2(6):714–732Google Scholar
  31. 202.
    Markovic O, Markovic N. MarkPap technology: a prospective for global cervical cancer control. FASEB annual meeting, experimental biology 2006, San FranciscoGoogle Scholar
  32. 203.
    Anhui Science Technology Company. www.ahnmst.com. Assessed June 2015
  33. 204.
    Anyon Biopharmaceuticals in Anhui, China. www.anyon.com.cn. Assessed July 2016
  34. 205.
    Anhui Anke Biotechnology Group Co, Ltd ankebio@mail.hf/ah.cn. Accessd July 2015Google Scholar
  35. 206.
    Markovic O, Markovic N (2007) Will home Pap test be soon available? Experimental biology 2007. The FASEB J 2007 21(6), A 754, 708.10. Click here to view the article
  36. 207.
    Markovic O, Markovic N (2012) Is mass cytological cancer screening possible worldwide? The FASEB J 26, 657.1. Click here to view the abstract
  37. 208.
    Markovic O, Markovic N. Meeting the recommendations for cervical cancer screening in developing counties. 2014 national conference on cancer detection, diagnosis and treatment for global health. NIH, Bethesda, January 2014. Click here to view
  38. 209.
    Markovic N, Markovic O (2008/2010) What every women should know about cervical cancer. Springer, Dordrecht. http://www.springer.com/biomed/cancer/book/978-1-4020-6936-9
  39. 210.
    www.bioscicon.com/gallery.htlm. Accessed June 2015
  40. 211.
  41. 212.
  42. 213.
    Markovic O, Markovic N (2013) IT telehealth center for telecytopathology. The FASEB J 27:874.20. Click here to view the abstract
  43. 214.
    Markovic N, Markovic O, Panashchenko O, McJonathan S. A tool for integration of cytology, HPV screening and telecytopathology. BIO 2008 international convention. San Diego, June 2008. Click here to download the abstract
  44. 215.
    Markovic O, Markovic N. IT enables same-day Pap test. Experimental Biology 2009, FASEB, April 2009. Click here to read the abstract
  45. 216.
    Markovic O, Markovic N. Cell phones as a new m-Health opportunity for mass cervical cancer screening. Experimental Biology 2010, FASEB, April 2010. Click here to read the abstract
  46. 217.
    BioSciCon’s most recent advances in wireless telecytopathology. Click here to view the document
  47. 218.
    Markovic O, Markovic N. Further studies on the application of wireless cytopathology for detection of cervical cancer and initial screening for oral cancer. FASEB national meeting, Experimental Biology 2011, Washington, DC, April 2011. Click here to download the abstract
  48. 219.
    Markovic O, Markovic N (2012) Universal adapter for telecytopathology. The FASEB J 26, 1b476. Click here to view the abstract

Copyright information

© Springer Science+Business Media B.V. 2016

Authors and Affiliations

  • Nenad Markovic
    • 1
  • Olivera Markovic
    • 2
  1. 1.Global Academy for Women’s Health, Inc.Medical Center DriveRockvilleUSA
  2. 2.Education Global Academy for Women’s Health, Inc.RockvilleUSA

Personalised recommendations